首页|期刊导航|世界中医药|复方苦参注射液联合拉帕替尼治疗Her-2阳性晚期乳腺癌疗效及对肿瘤标志物的影响

复方苦参注射液联合拉帕替尼治疗Her-2阳性晚期乳腺癌疗效及对肿瘤标志物的影响OACHSSCDCSTPCD

Curative Effect of Compound Kushen Injection Combined with Lapatinib Treatment of Her-2 Positive Advanced Breast Cancer and Effects on Tumor Markers

中文摘要英文摘要

目的:观察复方苦参注射液联合拉帕替尼治疗Her-2阳性晚期乳腺癌疗效及对肿瘤标志物的影响.方法:选取2013年5月至2017年6月辽宁中医药大学附属第二医院门诊及住院部就诊的Her-2阳性Ⅳ期的乳腺癌患者65例,按随机编号随机分为观察组和对照组,对照组使用拉帕替尼片口服治疗,观察组加以复方苦参注射液静脉滴注治疗,分别在治疗前及治疗18周后,对2组的临床疗效、生命质量、不良反应发生率、广谱肿瘤标志物、乳腺癌特异性肿瘤标志物进行比较分析.结果:在治疗…查看全部>>

Objective:To observe the effect of compound Kushen injection combined with lapatinib treatment of Her -2 positive ad-vanced breast cancer of and effect on tumor markers.Methods:A total of 65 cases of breast cancer of Her-2 positive stage Ⅳ in our hospital from May 2013 to June 2017 were randomly selected and divided into observation group and control group according to ran -dom numbers.The control group was given lapatinib tablets for oral treatment , and th…查看全部>>

秦海运;潘淑云;李政;李凤珍;王宁;胡鑫

辽宁省中医药研究院血液肿瘤科,沈阳,110034辽宁省中医药研究院医务处,沈阳,110034辽宁省肿瘤医院中西医结合科,沈阳,110034辽宁省中医药研究院血液肿瘤科,沈阳,110034辽宁省中医药研究院血液肿瘤科,沈阳,110034辽宁省中医药研究院血液肿瘤科,沈阳,110034

医药卫生

复方苦参注射液拉帕替尼Her-2阳性晚期乳腺癌免疫系统肿瘤标志物类胰岛素一号增长因子

Compound Kushen injectionLapatinibHer-2 positiveAdvancedBreast cancerImmune systemTumor mark-erIGF-1

《世界中医药》 2018 (6)

1472-1476,5

辽宁省中医药临床学(专)科能力建设项目(2014-lnzyxzk-05)

10.3969/j.issn.1673-7202.2018.06.040

评论

您当前未登录!去登录点击加载更多...